摘要
目的:系统评价坎地沙坦预防治疗偏头痛的疗效及安全性,为临床治疗提供循证医学证据。方法:通过检索PubMed、Embase、外文医学信息资源检索平台(FMRS)、Cochrane图书馆、中国期刊全文数据库(CNKI)、万方、维普等数据库中关于坎地沙坦预防治疗偏头痛的随机对照试验(RCT)。由两位研究者独立筛选文献、质量评价及提取数据,采用RevMan5.0统计软件进行Meta分析。结果:共纳入11项RCT,合计940例患者。Meta分析结果显示:坎地沙坦预防治疗偏头痛有效率高于对照组[OR=3.17,95%CI(2.06,4.87),P<0.05],安全性高于对照组[OR=0.28,95%CI(0.18,0.45),P<0.05]。坎地沙坦组在治疗后头痛发作频率、头痛持续时间、头痛强度等均低于对照组,差异有统计学意义(P<0.05)。结论:在预防治疗偏头痛中,坎地沙坦疗效和安全性优于氟桂利嗪和普萘洛尔。
Objective: To evaluate the curative effect and safety of candesartan for migraine prophylaxis and provide evidence-based medical evidence for clinical treatment.Methods: Published randomized controlled trials (RCTs) about candesartan for migraine prophylaxis were collected by a systematic search through PubMed, Embase, Foreign Medical Retrieval System, the Cochrane Library, CNKI, Wanfang and VIP database. Quality assessment and data extraction were conducted by two reviewers independently. Meta-analysis were conducted by RevMan 5.0 software.Results: A total of 11 RCTs involving 940 patients were included in this study. The results of meta-analysis showed that the total effective rate of candesartan group was significantly higher than that of the control group [OR = 3.17, 95%CI(2.06, 4.87), P < 0.05]. Safety of candesartan group was significantly higher than that of the control group [OR = 0.28, 95%CI(0.18, 0.45), P < 0.05]. Headache frequency, headache duration, headache severity after treatment of candesartan was significantly lower than those of the control group (P < 0.05). Conclusion: The curative effect and safety of candesartan for migraine prophylaxis were better than flunarizine and propranolol.
作者
王金明
洪伟勇
申慧玲
方芳
陈敏
WANG Jin-ming;HONG Wei-yong;SHEN Hui-ling;FANG Fang;CHEN Min(Municipal Hospital Affiliated to MedicalSchool of Taizhou University, Taizhou 318000, China;The 83rd Group Army Hospital of the People's Liberation Army of China, Xinxiang 453003,China;Yulin Hospital of Traditional Chinese Medicine, Yulin 719000, China;Third People's Hospital of Nantong City, Nantong 226001,China)
出处
《中国药物应用与监测》
CAS
2019年第3期132-136,共5页
Chinese Journal of Drug Application and Monitoring
基金
浙江省药学会医院药学专项科研项目(2014YY39)
椒江区科技项目(122083)
